Davis Polk advised the joint book-running managers in connection with the $207 million SEC-registered follow-on offering of common stock of Atara Biotherapeutics, Inc. The common stock is listed on The NASDAQ Global Market under the symbol “ATRA.”    

Based in South San Francisco, California, Atara Bio is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara Bio’s programs include molecularly targeted product candidates and T-cell product candidates.    

The Davis Polk corporate team included partner Bruce K. Dallas and associates Judy Lai and Stephanie Lai. The tax team included partner Rachel D. Kleinberg and associate Kelli A. Rivers. Associates Fiona Finlay-Hunt and Natalie A. Thomas provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.     

Copy link to share post